Movement Alert｜Zai Lab Falls 5.04% in Regular Trading, Partner Novocure Clinical Failure Continues to Weigh on Sentiment

Market Focus06-26 11:28

On June 26, Zai Lab fell 5.04% in regular trading, trading at approximately HK$13.8/share, with turnover of HK$97.96 million. The decline reflects continued fallout from partner Novocure's Phase 3 clinical trial failure combined with broad biotech sector weakness.

Novocure announced on June 18 that its Tumor Treating Fields (TTFields) therapy for glioblastoma failed to meet the overall survival primary endpoint in the Phase 3 TRIDENT trial, reporting HR of 0.953 and p-value of 0.519. Novocure plunged 20% on the announcement. Zai Lab holds Greater China commercial rights for TTFields, marketed domestically under the OPTUNE brand, and the negative pipeline valuation impact continues to be digested by the market.

Additionally, the company recently disclosed a Form 144 proposed securities sale filing, further pressuring market sentiment. Within the Biotechnology sector, AKESO fell 5.15%, INNOVENT BIO fell 2.17%, REMEGEN fell 2.36%, 3SBIO fell 0.87%, and BEIGENE fell 0.84%, indicating broad sector weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102423317?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102423317","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Zai Lab Falls 5.04% in Regular Trading, Partner Novocure Clinical Failure Continues to Weigh on Sentiment","media":"Market Focus","content":"<p><p>On June 26, Zai Lab fell 5.04% in regular trading, trading at approximately HK$13.8/share, with turnover of HK$97.96 million. The decline reflects continued fallout from partner Novocure's Phase 3 clinical trial failure combined with broad biotech sector weakness.</p><p>Novocure announced on June 18 that its Tumor Treating Fields (TTFields) therapy for glioblastoma failed to meet the overall survival primary endpoint in the Phase 3 TRIDENT trial, reporting HR of 0.953 and p-value of 0.519. Novocure plunged 20% on the announcement. Zai Lab holds Greater China commercial rights for TTFields, marketed domestically under the OPTUNE brand, and the negative pipeline valuation impact continues to be digested by the market.</p><p>Additionally, the company recently disclosed a Form 144 proposed securities sale filing, further pressuring market sentiment. Within the Biotechnology sector, AKESO fell 5.15%, INNOVENT BIO fell 2.17%, REMEGEN fell 2.36%, 3SBIO fell 0.87%, and BEIGENE fell 0.84%, indicating broad sector weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Zai Lab Falls 5.04% in Regular Trading, Partner Novocure Clinical Failure Continues to Weigh on Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Zai Lab Falls 5.04% in Regular Trading, Partner Novocure Clinical Failure Continues to Weigh on Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 11:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Zai Lab fell 5.04% in regular trading, trading at approximately HK$13.8/share, with turnover of HK$97.96 million. The decline reflects continued fallout from partner Novocure's Phase 3 clinical trial failure combined with broad biotech sector weakness.</p><p>Novocure announced on June 18 that its Tumor Treating Fields (TTFields) therapy for glioblastoma failed to meet the overall survival primary endpoint in the Phase 3 TRIDENT trial, reporting HR of 0.953 and p-value of 0.519. Novocure plunged 20% on the announcement. Zai Lab holds Greater China commercial rights for TTFields, marketed domestically under the OPTUNE brand, and the negative pipeline valuation impact continues to be digested by the market.</p><p>Additionally, the company recently disclosed a Form 144 proposed securities sale filing, further pressuring market sentiment. Within the Biotechnology sector, AKESO fell 5.15%, INNOVENT BIO fell 2.17%, REMEGEN fell 2.36%, 3SBIO fell 0.87%, and BEIGENE fell 0.84%, indicating broad sector weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1102423317","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102423317","pubTimestamp":1782444534,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Zai Lab fell 5.04% in regular trading, trading at approximately HK$13.8/share, with turnover of HK$97.96 million. The decline reflects continued fallout from partner Novocure's Phase 3...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"动向提示|再鼎医药常规交易跌5.04%合作伙伴Novocure临床失败继续打压市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On June 26, Zai Lab fell 5.04% in regular trading, trading at approximately HK$13.8/share, with turnover of HK$97.96 million. The decline reflects continued fallout from partner Novocure's Phase 3 clinical trial failure combined with broad biotech sector weakness.Novocure announced on June 18 that its Tumor Treating Fields (TTFields) therapy for glioblastoma failed to meet the overall survival primary endpoint in the Phase 3 TRIDENT trial, reporting HR of 0.953 and p-value of 0.519. Novocure plunged 20% on the announcement. Zai Lab holds Greater China commercial rights for TTFields, marketed domestically under the OPTUNE brand, and the negative pipeline valuation impact continues to be digested by the market.Additionally, the company recently disclosed a Form 144 proposed securities sale filing, further pressuring market sentiment. Within the Biotechnology sector, AKESO fell 5.15%, INNOVENT BIO fell 2.17%, REMEGEN fell 2.36%, 3SBIO fell 0.87%, and BEIGENE fell 0.84%, indicating broad sector weakness.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102423317","isCrawlerRequest":true}